ALCOX — Nicox SA Share News
0.000.00%
Last trade - 00:00- €32.43m
- €28.69m
- €16.77m
Brief: Nicox H1 Operating Loss Widens To 7.6 Million Euros
Brief: Nicox Completes Enrollment Of Adaptive Design Cohort Of NCX470 Mont Blanc Phase 3 Trial
Brief: French group Nicox strikes deal with ITROM for 'ZERVIATE' product in Gulf and Arab markets
Brief: French ophthalmology company Nicox in talks over 2 mln euros loan backed by French state
Brief: Nicox Q2 Net Revenue At 0.6 Million Euros
Brief: Nicox: Enrollment Progress In Mont Blanc Phase 3 Clinical Trial
Brief: Nicox Partner Ocumension Completes Successful Hong Kong IPO At About US$ 1.09 Bln Valuation
Brief: Nicox Sells Its Remaining Stake In VISUfarma For 5 Million Euros
Brief: Nicox Initiates First Phase 3 Trial Of NCX 470 In Glaucoma
Brief: Nicox Announces Q1 Net Revenue Of 1.7 Million Euros
Brief: Nicox Outlines Plans To Progress NCX 4251 Into Phase 2b Trial
Brief: Nicox: Partner Fera Pharmaceuticals Applies For Orphan Drug Designation For Naproxcinod
Brief: Nicox Announces Zerviate Launch By Eyevance Pharmaceuticals In The U.S.
Brief: Nicox Announces Additional Approval For Vyzulta In Taiwan
Brief: Nicox FY Net Revenue Up At 6.9 Million Euros
Brief: Nicox Completes End-of-Phase 2 Meeting With the U.S. FDA
Brief: Nicox Receives Formulation Patent Extending
Brief: Nicox Q4 2019 Net Revenue Down At 0.6 Million Euros
Brief: Nicox’s Partner Secures Additional Approvals Of VYZULTA